Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Apr;29(4):1228-1234.
doi: 10.1007/s10461-024-04597-4. Epub 2025 Jan 9.

Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study

V Iannone  1 , F Lombardi  2   3 , A Ciccullo  4 , F Lamanna  1 , P F Salvo  1 , A Sanfilippo  1 , G Baldin  5 , A Borghetti  6 , C Torti  5 , S Di Giambenedetto  1   5
Affiliations
Observational Study

Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study

V Iannone et al. AIDS Behav. 2025 Apr.

Abstract

The new Cabotegravir + Rilpivirine long acting (CAB + RPV) is the injectable regimen for treatment-experienced people with HIV (PWH). Little data from real-world settings are available, particularly in more complex PWH. We aimed to investigate the effectiveness of CAB + RPV in our real-life cohort of experienced PWH. We conducted a prospective observational longitudinal study by enrolling PWH who switched to CAB + RPV. We recruited participants from our outpatient clinic and a lower percentage of complex PWH followed by our home-care assistance (HCA). We evaluated time to virological failure (VF) and time to treatment discontinuation (TD) for any cause using Cox regression analyses. In the subgroup followed by HCA we also analyzed the total HIV-DNA trend during the study period. We enrolled 62 participants: 52 were outpatients (83.9%) and 10 followed by HCA (16.1%). Mostly were males (66.1%), with a median age of 51 years (IQR 31-60). During a 31.5 person-years follow-up (PYFU), all participants maintained virological suppression (< 30cps/mL). We observed 9 discontinuations during follow-up, with a rate of discontinuation of 28.6 per 100 PYFU. The estimated probabilities of maintaining CAB + RPV at 24 and 48 weeks were 84.9% (SD: 0.5) and 79.2% (SD: 0.7), respectively. No significant predictors of discontinuations were found. In the subgroup, we found no significant changes in the HIV-DNA levels over time (p = 0.332). Our results confirm the efficacy of CAB + RPV as a switch strategy in virologically suppressed PWH and even in more complex individuals, encouraging its use in PWH in need, coupled with HCA home administration support.

Keywords: Antiretroviral Therapy; Complex PWH; Long-acting Injectable; Parenteral Regimen.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: A.C. received support for travel to meetings from ViiV Healthcare. A.B. received a speakers’ honoraria from ViiV Healthcare, and fees for attending advisory boards from Janssen-Cilag, S.D.G. was a paid consultant or member of the advisory boards for Gilead Sciences, ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme and Bristol-Myers Squibb. None of the other authors have anything to declare. Ethical Approval: The study protocol and informed consent documents were reviewed and approved by our local Ethics Committee (Fondazione Policlinico Universitario A. Gemelli IRCCS) (7768/16). Consent to Participate: Individual consent was obtained before participation of the study.

References

    1. Flamm J, Garris C, D’Amico R, et al. Pb4 patient perspectives on implementation of a long-acting Injectable antiretroviral therapy regimen in HIV US Healthcare settings: final month 12 results from the CUSTOMIZE study. Value Health. 2021;24:S13. https://doi.org/10.1016/j.jval.2021.04.070 . - DOI
    1. Farooq HZ, Apea V, Kasadha B, et al. Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritized people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design. BMJ Open. 2023;13:e070666. https://doi.org/10.1136/bmjopen-2022-070666 . - DOI - PubMed - PMC
    1. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10:e566–77. - DOI - PubMed
    1. Delle Donne V, Massaroni V, Lombardi F, et al. The association between stigma and wellbeing in an Italian cohort of PWH: the role of social support and personal factors. Int J STD AIDS. 2023;9564624231213115. https://doi.org/10.1177/09564624231213115 .
    1. Gandhi M, Hickey M, Imbert E, et al. Demonstration project of long-acting antiretroviral therapy in a Diverse Population of people with HIV. Ann Intern Med. 2023;176:969–74. - DOI - PubMed - PMC

Publication types

LinkOut - more resources